ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » Alabama » Hematology Oncology

Top Hematology Oncology Prescribers in Alabama

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
JEFFREY GEORGE MD

Hematology Oncology

3,446

$1.41M

459
331 are 65+

19%
patients receiving schedule two controlled substances

Avg: 16%

39%
patients receiving schedule three controlled substances

Avg: 21%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 3%

21%
prescriptions for brand name drugs

Avg: 17%

$410
Average prescription price

Avg: $365

ALLEN YEILDING MD

Hematology Oncology

3,225

$427K

272
199 are 65+

18%
patients receiving schedule two controlled substances

Avg: 16%

35%
patients receiving schedule three controlled substances

Avg: 21%

5%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 3%

14%
prescriptions for brand name drugs

Avg: 17%

$132
Average prescription price

Avg: $365

DANIEL CAMERON M.D.

Hematology Oncology

3,216

$1.45M

405
297 are 65+

16%
patients receiving schedule two controlled substances

Avg: 16%

20%
patients receiving schedule three controlled substances

Avg: 21%

5%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 3%

16%
prescriptions for brand name drugs

Avg: 17%

$450
Average prescription price

Avg: $365

STEPHEN DAVIDSON MD

Hematology Oncology

2,940

$935K

362
263 are 65+

21%
patients receiving schedule two controlled substances

Avg: 16%

25%
patients receiving schedule three controlled substances

Avg: 21%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 3%

20%
prescriptions for brand name drugs

Avg: 17%

$318
Average prescription price

Avg: $365

ALI HACHEM M.D.

Hematology Oncology

2,523

$835K

168
113 are 65+

21%
patients receiving schedule two controlled substances

Avg: 16%

41%
patients receiving schedule three controlled substances

Avg: 21%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 3%

18%
prescriptions for brand name drugs

Avg: 17%

$331
Average prescription price

Avg: $365

JOHN REARDON M.D.

Hematology Oncology

2,455

$915K

332
236 are 65+

18%
patients receiving schedule two controlled substances

Avg: 16%

22%
patients receiving schedule three controlled substances

Avg: 21%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 3%

16%
prescriptions for brand name drugs

Avg: 17%

$373
Average prescription price

Avg: $365

STEPHEN WHITE MD

Hematology Oncology

2,415

$711K

261
196 are 65+

9%
patients receiving schedule two controlled substances

Avg: 16%

18%
patients receiving schedule three controlled substances

Avg: 21%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 3%

18%
prescriptions for brand name drugs

Avg: 17%

$295
Average prescription price

Avg: $365

WILLIAM CUMBIE MD

Hematology Oncology

2,389

$119K

169
150 are 65+

0%
patients receiving schedule two controlled substances

Avg: 16%

0%
patients receiving schedule three controlled substances

Avg: 21%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 3%

27%
prescriptions for brand name drugs

Avg: 17%

$50
Average prescription price

Avg: $365

JAMES LASKER M.D.

Hematology Oncology

2,288

$763K

281
191 are 65+

21%
patients receiving schedule two controlled substances

Avg: 16%

38%
patients receiving schedule three controlled substances

Avg: 21%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 3%

13%
prescriptions for brand name drugs

Avg: 17%

$333
Average prescription price

Avg: $365

HARRY BARNES MD

Hematology Oncology

2,283

$951K

272
202 are 65+

15%
patients receiving schedule two controlled substances

Avg: 16%

27%
patients receiving schedule three controlled substances

Avg: 21%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 3%

21%
prescriptions for brand name drugs

Avg: 17%

$417
Average prescription price

Avg: $365

SAMMY BECDACH M.D.

Hematology Oncology

2,271

$346K

238
188 are 65+

16%
patients receiving schedule two controlled substances

Avg: 16%

23%
patients receiving schedule three controlled substances

Avg: 21%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 3%

16%
prescriptions for brand name drugs

Avg: 17%

$152
Average prescription price

Avg: $365

SUSAN FERGUSON M.D.

Hematology Oncology

2,210

$842K

278
209 are 65+

12%
patients receiving schedule two controlled substances

Avg: 16%

14%
patients receiving schedule three controlled substances

Avg: 21%

4%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 3%

19%
prescriptions for brand name drugs

Avg: 17%

$381
Average prescription price

Avg: $365

SCOTT MCDANIEL MD

Hematology Oncology

2,197

$532K

210
156 are 65+

16%
patients receiving schedule two controlled substances

Avg: 16%

23%
patients receiving schedule three controlled substances

Avg: 21%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 3%

17%
prescriptions for brand name drugs

Avg: 17%

$242
Average prescription price

Avg: $365

SHAILENDRA LAKHANPAL M.D.

Hematology Oncology

2,123

$501K

304
265 are 65+

8%
patients receiving schedule two controlled substances

Avg: 16%

13%
patients receiving schedule three controlled substances

Avg: 21%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 3%

10%
prescriptions for brand name drugs

Avg: 17%

$236
Average prescription price

Avg: $365

JONATHAN BRIDGES MD

Hematology Oncology

2,112

$503K

263
181 are 65+

16%
patients receiving schedule two controlled substances

Avg: 16%

22%
patients receiving schedule three controlled substances

Avg: 21%

5%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 3%

16%
prescriptions for brand name drugs

Avg: 17%

$238
Average prescription price

Avg: $365

KEITH THOMPSON MD

Hematology Oncology

2,098

$610K

264
187 are 65+

17%
patients receiving schedule two controlled substances

Avg: 16%

30%
patients receiving schedule three controlled substances

Avg: 21%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 3%

14%
prescriptions for brand name drugs

Avg: 17%

$291
Average prescription price

Avg: $365

JAMES CANTRELL M.D.

Hematology Oncology

2,096

$604K

300
244 are 65+

13%
patients receiving schedule two controlled substances

Avg: 16%

18%
patients receiving schedule three controlled substances

Avg: 21%

4%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 3%

15%
prescriptions for brand name drugs

Avg: 17%

$288
Average prescription price

Avg: $365

JOANNE ROSSMAN M.D.

Hematology Oncology

1,999

$484K

240
182 are 65+

21%
patients receiving schedule two controlled substances

Avg: 16%

29%
patients receiving schedule three controlled substances

Avg: 21%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 3%

15%
prescriptions for brand name drugs

Avg: 17%

$242
Average prescription price

Avg: $365

KATISHA VANCE M.D.

Hematology Oncology

1,934

$264K

222
147 are 65+

14%
patients receiving schedule two controlled substances

Avg: 16%

19%
patients receiving schedule three controlled substances

Avg: 21%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 3%

15%
prescriptions for brand name drugs

Avg: 17%

$136
Average prescription price

Avg: $365

MICHAEL MESHAD MD

Hematology Oncology

1,915

$1.07M

291
236 are 65+

13%
patients receiving schedule two controlled substances

Avg: 16%

20%
patients receiving schedule three controlled substances

Avg: 21%

6%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 3%

17%
prescriptions for brand name drugs

Avg: 17%

$560
Average prescription price

Avg: $365

DAVID CLARKSON M.D.

Hematology Oncology

1,800

$855K

269
190 are 65+

19%
patients receiving schedule two controlled substances

Avg: 16%

28%
patients receiving schedule three controlled substances

Avg: 21%

6%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 3%

19%
prescriptions for brand name drugs

Avg: 17%

$475
Average prescription price

Avg: $365

THOMAS BROWN M.D.

Hematology Oncology

1,787

$1.31M

246
174 are 65+

15%
patients receiving schedule two controlled substances

Avg: 16%

21%
patients receiving schedule three controlled substances

Avg: 21%

5%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 3%

22%
prescriptions for brand name drugs

Avg: 17%

$732
Average prescription price

Avg: $365

KHALEEL ASHRAF M.D.

Hematology Oncology

1,737

$687K

224
159 are 65+

18%
patients receiving schedule two controlled substances

Avg: 16%

19%
patients receiving schedule three controlled substances

Avg: 21%

6%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 3%

15%
prescriptions for brand name drugs

Avg: 17%

$396
Average prescription price

Avg: $365

STEPHEN BECK M.D.

Hematology Oncology

1,713

$753K

204
154 are 65+

19%
patients receiving schedule two controlled substances

Avg: 16%

17%
patients receiving schedule three controlled substances

Avg: 21%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 3%

17%
prescriptions for brand name drugs

Avg: 17%

$440
Average prescription price

Avg: $365

PHILIP MCGEE M.D.

Hematology Oncology

1,681

$221K

169
112 are 65+

22%
patients receiving schedule two controlled substances

Avg: 16%

25%
patients receiving schedule three controlled substances

Avg: 21%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 3%

16%
prescriptions for brand name drugs

Avg: 17%

$132
Average prescription price

Avg: $365

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank